Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9288270 | 0.85 | AKR1C3 (0.39) | GABRA1GABRB1PARP14NR4A2MEN1 | |
| Lithium SCHEMBL17802201 | 0.84 | AKR1C3 (0.38) | GABRA1GABRB1PARP14NR4A2MEN1 | |
| SCHEMBL19328315 | 0.84 | AKR1C4 (0.38) | GABRA1GABRB1PARP14NR4A2MEN1 | |
| SCHEMBL17802163 | 0.81 | NR4A2 (0.49) | GABRA1GABRB1PARP14NR4A2ALDH1A1 | |
| SCHEMBL19708400 | 0.77 | GABRA1 (0.41) | GABRA1GABRB1PARP14 | |
| SCHEMBL31022882 | 0.73 | GABRA1 (0.42) | GABRA1GABRB1NR4A2ALDH1A1HSD17B10 | |
| SCHEMBL5673618 | 0.73 | GABRA1 (0.39) | GABRA1GABRB1PARP14 | |
| SCHEMBL9283757 | 0.71 | GABRA1 (0.38) | GABRA1GABRB1PARP14 | |
| SCHEMBL31023069 | 0.71 | GABRA1 (0.40) | GABRA1GABRB1PARP14NR4A2ALDH1A1 | |
| SCHEMBL30993004 | 0.69 | CREBBP (0.45) | GABRA1GABRB1PARP14NR4A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227275-B1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-9840496-B2 | CD38 inhibitors and methods of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-20170260164-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260164-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | CD38, NQO1, NADK | GABRA1 3799/4885GABRB1 3334/4885PARP14 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.